AstraZeneca Breztri met primary endpoints in Phase III trials in asthma
AstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines. […]